Patent US4078065A successfully refreshed from Google Patents.
US4078065A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Organic compounds
Assignee: Sandoz AG
•
Filing: 1976-07-02
•
Granted: 1978-03-07
•
Expires: 1996-07-02
Abstract
Abstract The present invention relates to a pharmaceutical composition comprising aggregates of diameter of at most 20,000 A, comprising:
Inventors
- 👤 Joachim Franz
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 17:14
CPC Classifications
A; A61; A61K; A61K47/00; A61K47/44
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
55 words
A pharmaceutical composition comprising aggregates of diameter of at most 20,000 A, comprising component a) a therapeutically effective amount of ergot alkaloid, and component b) a pharmaceutically acceptable ethoxylated cholesterin emulsifier having an HLB value of from 10 to 30 and present in an amount greater than 10 times by weight of the ergot alkaloid.
Claim 2
Dependent Claim
55 words
A pharmaceutical composition comprising aggregates of diameter of at most 20,000 A, comprising component a) a therapeutically effective amount of ergot alkaloid, and component b) a pharmaceutically acceptable ethoxylated cholesterin emulsifier having an HLB value of from 10 to 30 and present in an amount greater than 10 times by weight of the ergot alkaloid.
Claim 3
Dependent Claim
26 words
A pharmaceutical composition according to claim 1, wherein the ergot alkaloid is chosen from dihydroergotoxine, dihydroergocristine, 13-bromodihydroergocristine, dihydroergonine, dihydroergocryptine, dihydroergotamine, 13-bromodihydroergotamine, dihydroergocornine and dihydroergovaline, and ergotamine.
Claim 4
Dependent Claim
12 words
A pharmaceutical composition according to claim 1 wherein ergot alkalid is dihydroergonine,
Claim 5
Dependent Claim
25 words
A pharmaceutical composition according to claim 1, wherein the ratio of component b) to component a) is from 10 to 1 to 50 to 1.
Claim 6
Dependent Claim
25 words
A pharmaceutical composition according to claim 16, wherein the ratio of component b) to component a) is from 12 to 1 to 25 to 1.
Claim 7
Dependent Claim
20 words
A pharmaceutical composition according to claim 5, wherein the ratio of component b) to component a) is 25 to 1.
Claim 8
Dependent Claim
23 words
A pharmaceutical composition according to claim 1, wherein component b) is cholesterin ethoxylated with approximately 24 moles of ethylene oxide per mole cholesterin.
Claim 9
Independent Claim
71 words
A method of increasing the enteral absorption of ergot alkaloids which comprises administering the alkaloid in a pharmaceutical composition comprising aggregates of diameter of at most 20,000 A, comprising component a) a therapeutically effective amount of ergot alkaloid, and component b) a pharmaceutically acceptable ethoxylated cholesterin emulsifer having an HLB value of from 10 to 30 and present in an amount greater than 10 times by weight of the ergot alkaloid.
Claim 10
Independent Claim
71 words
A method of increasing the enteral absorption of ergot alkaloids which comprises administering the alkaloid in a pharmaceutical composition comprising aggregates of diameter of at most 20,000 A, comprising component a) a therapeutically effective amount of ergot alkaloid, and component b) a pharmaceutically acceptable ethoxylated cholesterin emulsifer having an HLB value of from 10 to 30 and present in an amount greater than 10 times by weight of the ergot alkaloid.
Claim 11
Dependent Claim
25 words
A method according to claim 8, wherein the ergot alkaloid is chosen from dihydroergotoxine, dihydroergocristine, 13-bromodihydroergocristine, dihydroergonine, dihydroergocryptine, dihydroergotamine, 13-bromodihydroergotamine, dihydroergocornine and dihydroergovaline, and ergotamine.
Claim 12
Dependent Claim
11 words
A method according to claim 8, wherein ergot alkaloid is dihydroergonine.
Claim 13
Dependent Claim
24 words
A method according to claim 8, wherein the ratio of component b) to component a) is from 10 to 1 to 50 to 1.
Claim 14
Dependent Claim
24 words
A method according to claim 8, wherein the ratio of component b) to component a) is from 12 to 1 to 25 to 1.
Claim 15
Dependent Claim
19 words
A method according to claim 8, wherein the ratio of component b) to component a) is 25 to 1.
Claim 16
Dependent Claim
22 words
A method according to claim 8, wherein component b) is cholesterin ethoxylated with approximately 24 moles of ethylene oxide per mole cholesterin.
Claim 17
Dependent Claim
10 words
An ampoule containing a pharmaceutical composition according to claim 1.
Claim 18
Dependent Claim
13 words
A pharmaceutical composition according to claim 1, in the form of a capsule.
Claim 19
Dependent Claim
15 words
A pharmaceutical composition according to claim 1, in the form of a water-containing drop solution.
Claim 20
Dependent Claim
24 words
A pharmaceutical composition according to claim 1 in association with a pharmaceutically acceptable non-aqueous liquid carrier in the form of an anhydrous drop solution.
Claim 21
Dependent Claim
13 words
A pharmaceutical composition according to claim 1, in the form of a tablet.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1981-03-06 | 1981-09-05 | 1982-03-07 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1985-03-06 | 1985-09-05 | 1986-03-07 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1989-03-06 | 1989-09-05 | 1990-03-07 | $7700.00 | Window Closed / Lapsed |